Search
Now showing items 1-4 of 4
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol
(
Elsevier
, 2016 , Article)
Background Atorvastatin and metformin are known energy restricting mimetic agents that act synergistically to produce molecular and metabolic changes in advanced prostate cancer (PCa). This trial seeks to determine whether ...
Prostate biopsy, targeted prophylaxis and infectious complications: a critique of methods used
(
Wiley
, 2016 , Article)
Commentary
68 Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer
(
Springer
, 2020 , Article)
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) improves prostate cancer staging. Intraprostatic PSMA intensity may ...
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer
(
Springer
, 2021 , Other)
Figure 2b is incorrect in the original paper, the correct Fig. 2 is shown below: (Figure presented.).